News

Fundamentals of Real World Evidence for Optimising Market Access

Join us on the 21st November at the Courtyard Marriott Brussels Hotel for an informative workshop on ‘Fundamentals of real-world evidence for optimising market access’.

Click on the picture below for further information and to register.

By |2019-10-09T11:56:43+00:00October 9th, 2019|News|Comments Off on Fundamentals of Real World Evidence for Optimising Market Access

Our 4th abstract accepted at ISPOR 2019

“Pricing and market access launch excellence: what are the key challenges facing companies today?”

OBJECTIVES

Optimising market access is increasingly important during drug launches, with growing healthcare expenditure meaning payers are more stringent regarding the evidence needed to achieve reimbursement at a high price. This study aims to understand the industry perspective on drivers and challenges for a successful launch from a pricing and market access (PMA) perspective, and the areas that can be improved in future.

METHODS

15 executives from top pharmaceutical companies completed an online survey, covering the following key topics:

  • Whether recent PMA launches had met expectations
  • The main internal company and payer / health technology assessment (HTA) challenges faced
  • Factors that would improve future PMA launches

The sample comprised a mix of personnel across PMA teams and Commercial teams.

RESULTS

81% of the sample had launched either an innovative biologic or small molecule in the previous 5 years, with 38% considering their […]

By |2019-10-09T10:45:06+00:00October 3rd, 2019|News|Comments Off on Our 4th abstract accepted at ISPOR 2019

New international reference pricing rules for Greece in 2019. What is the impact and will drug prices rise or fall?

Medicine prices in Greece are set by international reference pricing (IRP). IRP is the process of using the prices in other countries to set the price of the drug. Greece has used IRP for many years to determine the price of new products entering the market. Historically, the price has been calculated based on an average basket of the lowest three ex-factory prices from the 28 EU member states.

However, the Greek government has put forward proposals to update the IRP methodology and basket of countries. These changes include:

  • Prices will only be considered within the 19 eurozone countries
  • A price must be available in a minimum of 3 eurozone country
  • The Greek ex-factory price is an average of the 2 lowest different eurozone countries price
  • International reference pricing will occur once a year.

What are the benefits of this new approach?

Firstly, by using eurozone countries, it removes exchange rate […]

By |2019-09-26T09:43:28+00:00September 26th, 2019|News|Comments Off on New international reference pricing rules for Greece in 2019. What is the impact and will drug prices rise or fall?

5th Birthday Celebrations

The Remap Consulting team had a fantastic time on Saturday with their families in Manchester, celebrating a very successful 5 years in business.

The sun shone, chocolates were won and a great time was had by all with some beautiful food and flowing drinks.

Cheers Remap Consulting! And a very Happy 5th Birthday!

 

By |2019-09-25T13:54:03+00:00September 25th, 2019|News|Comments Off on 5th Birthday Celebrations

Fundamentals of Real World Evidence for Optimising Market Access

Join us on the 21st November at the Courtyard Marriott Brussels Hotel for an informative workshop on ‘Fundamentals of real-world evidence for optimising market access’.

Click on the picture below for further information and to register.

By |2019-09-13T15:21:16+00:00September 16th, 2019|News|Comments Off on Fundamentals of Real World Evidence for Optimising Market Access

Our 3rd abstract accepted at ISPOR 2019

“Was the evidence base for Yescarta and Kymriah sufficient to justify their cost and secure patient access across 6 markets?”

OBJECTIVES

To determine whether the evidence base for high-cost CAR T-cell therapies tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) was sufficient to be granted reimbursement by European HTA bodies (Transparency Committee (TC), France; G-BA, Germany; TLV, Sweden; NICE, UK) and ICER (US), and specifically how gaps in the current evidence are linked to access restrictions.

METHODS

NICE, G-BA, TLV, ICER and TC HTA reports were identified for Yescarta in the diffuse large B-cell lymphoma (DLBCL) indication and Kymriah in the acute lymphoblastic leukaemia (ALL) and DLBCL indications. These reports were assessed against a pre-defined criterion to understand whether the clinical and economic evidence was sufficient at launch to secure reimbursement. Evidence gaps were identified, and recommendations to address these gaps were compared across the five countries.

RESULTS

Despite the high treatment costs, patients can access these treatments […]

By |2019-10-03T10:24:41+00:00September 13th, 2019|News|Comments Off on Our 3rd abstract accepted at ISPOR 2019

Remap Consulting welcomes Edward Rigby to the team!

We are delighted to announce the appointment of Edward Rigby as an Analyst at Remap Consulting.

Prior to joining us, Edward was an intern consultant at IP Pragmatics, where he gained experience of market research and patent landscape analysis, while assisting in the commercialisation of new technologies within biosciences. Edward has experience of working within a number of research areas, including genetics, medical devices and plant sciences.

Edward has a BSc in Genetics from the University of Liverpool.

Outside of work, Edward enjoys playing badminton, cycling and fencing.

We are sure Edward is going to settle in really well with us!

By |2019-09-06T15:10:00+00:00September 6th, 2019|Careers, News|Comments Off on Remap Consulting welcomes Edward Rigby to the team!

What are the pricing and market access launch challenges facing companies today? The results of our survey are in!

Over the last 3 months, we have been conducting a survey to understand pricing and market access launch drivers and challenges for a successful PMA launch, and the areas that can be improved for future launches. We are delighted to say that we have received fabulous feedback, with responses from at least 15 industry executives across global pharma companies.

Key findings include:

  • Internal company barriers (e.g. budget/personnel) are rarely considered a significant challenge by pricing and market access teams.
  • Pricing and market access teams now form a core part of the Commercial launch team and are considered a ‘strategic partner’ in 31% of cases.
  • Most recent pricing and market access launches faced evidence challenges during payer negotiations, such as endpoint and comparator selection, and patient subpopulation data.
  • Pricing and market access teams must be involved earlier in the clinical development process to ensure that the necessary clinical and economic evidence is […]
By |2019-09-06T13:16:56+00:00September 5th, 2019|News, Publications|Comments Off on What are the pricing and market access launch challenges facing companies today? The results of our survey are in!